Additionally, a meta-analysis by Arnold et al. (including the CRYSTAL, FIRE-3, CALGB 80405, PRIME, PEAK, and 20050181 studies) confirmed the prognostic value of primary tumor location and demonstrated that patients with left-sided tumors significantly benefited from an anti-EGFR antibody plus chemotherapy vs. chemotherapy with or without bevacizumab. The gene discussed is EGFR; the disease is neoplasm.